Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Shares Outstanding (Diluted Average) (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed Shares Outstanding (Diluted Average) for 6 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 14.27% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, up 14.27% year-over-year, with the annual reading at $3.3 million for FY2023, 127.22% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $10.0 million at Aytu Biopharma, down from $19.5 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $19.5 million in Q3 2025, with the low at $1.3 million in Q3 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $6.3 million, with a median of $5.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) plummeted 91.22% in 2022, then soared 151.05% in 2023.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $1.3 million in 2021, then soared by 135.52% to $3.1 million in 2022, then skyrocketed by 77.4% to $5.5 million in 2023, then surged by 59.18% to $8.8 million in 2024, then grew by 14.27% to $10.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $10.0 million, $19.5 million, and $8.2 million for Q4 2025, Q3 2025, and Q1 2025 respectively.